Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) announces that it has successfully completed the acquisition of IVERIC bio, Inc. (NASDAQ: ISEE, CEO: Glenn P. Sblendorio, “Iveric Bio”) with respect to the announcement on April 30, 2023, through its indirect wholly-owned subsidiary Berry Merger Sub, Inc. (the “Acquisition”). The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become Astellas’ wholly-owned subsidiary.
Read the full article: Astellas Completes Acquisition of Iveric Bio //
Source: https://www.prnewswire.com/news-releases/astellas-completes-acquisition-of-iveric-bio-301874923.html